The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
127881151 12788115 1 I 2005 20160916 20160928 20160928 PER US-ASTRAZENECA-2016SF00482 ASTRAZENECA 50.00 YR F Y 90.30000 KG 20160928 US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
127881151 12788115 1 PS SEROQUEL XR QUETIAPINE FUMARATE 1 Oral 219300 MG Y U 22047 300 MG PROLONGED-RELEASE TABLET QD
127881151 12788115 2 SS SEROQUEL XR QUETIAPINE FUMARATE 1 Oral 219300 MG Y U 22047 300 MG PROLONGED-RELEASE TABLET QD
127881151 12788115 3 C MAVIK TRANDOLAPRIL 1 Oral 0 4 MG QD
127881151 12788115 4 C GABAPENTIN. GABAPENTIN 1 Oral 0 300 MG TID
127881151 12788115 5 C SINGULAIR MONTELUKAST SODIUM 1 Oral GENERIC 0 10 MG QD
127881151 12788115 6 C CYMBALTA DULOXETINE HYDROCHLORIDE 1 Oral 0 60 MG QD
127881151 12788115 7 C LAMOTRIGINE. LAMOTRIGINE 1 Oral 0 100 MG QD
127881151 12788115 8 C LAMOTRIGINE. LAMOTRIGINE 1 Oral 0 100 MG QD
127881151 12788115 9 C LIPITOR ATORVASTATIN CALCIUM 1 Oral GENERIC 0 10 MG QD
127881151 12788115 10 C HYDROXYZINE HYDROXYZINEHYDROXYZINE HYDROCHLORIDE 1 Oral 0 50 MG QD
127881151 12788115 11 C TRILEPTAL OXCARBAZEPINE 1 Oral GENERIC 0 600 MG QD
127881151 12788115 12 C TRILEPTAL OXCARBAZEPINE 1 Oral GENERIC 0 600 MG QD
127881151 12788115 13 C CLONAZEPAM. CLONAZEPAM 1 Oral 0 .5 MG QD
127881151 12788115 14 C CLONAZEPAM. CLONAZEPAM 1 Oral 0 .5 MG QD
127881151 12788115 15 C REMERON MIRTAZAPINE 1 Oral 0 15 MG QD

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
127881151 12788115 1 Bipolar disorder
127881151 12788115 2 Sleep disorder
127881151 12788115 3 Hypertension
127881151 12788115 4 Neuropathy peripheral
127881151 12788115 5 Multiple allergies
127881151 12788115 6 Depression
127881151 12788115 7 Depression
127881151 12788115 8 Bipolar disorder
127881151 12788115 9 Blood cholesterol abnormal
127881151 12788115 10 Sleep disorder
127881151 12788115 11 Sleep disorder
127881151 12788115 12 Bipolar disorder
127881151 12788115 13 Sleep disorder
127881151 12788115 14 Tardive dyskinesia
127881151 12788115 15 Sleep disorder

Outcome of event

no results found

Reactions reported

Event ID CASEID DRUG REC ACT PT
127881151 12788115 Dyskinesia
127881151 12788115 Off label use
127881151 12788115 Product use issue

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
127881151 12788115 1 2005 0
127881151 12788115 2 2005 0
127881151 12788115 3 1996 0
127881151 12788115 4 1999 0
127881151 12788115 5 2013 0
127881151 12788115 6 2013 0
127881151 12788115 7 2012 0
127881151 12788115 8 2012 0
127881151 12788115 9 1991 0
127881151 12788115 10 2015 0
127881151 12788115 11 2015 0
127881151 12788115 12 2015 0
127881151 12788115 13 2014 0
127881151 12788115 14 2014 0
127881151 12788115 15 201603 0